Advent Technologies (ADN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The annual meeting is scheduled for December 31, 2024, in a virtual format, with stockholders able to vote online, by phone, mail, or during the meeting.
Stockholders will vote on electing one director, ratifying the appointment of the independent auditor, and any other business that may arise.
The record date for voting eligibility is November 27, 2024, with 2,636,508 shares outstanding.
Voting matters and shareholder proposals
Proposal 1: Elect one Class I director (Robert W. Schwartz) to serve until the 2027 annual meeting.
Proposal 2: Ratify M & K CPAS, PLLC as the independent registered public accounting firm for 2024.
Proposal 3: Approve the transaction of other business and potential adjournment if needed.
Board recommends voting FOR all proposals.
Stockholders may submit proposals for the 2025 meeting by September 2, 2025.
Board of directors and corporate governance
The board consists of six members divided into three classes with staggered three-year terms.
Four directors are considered independent under Nasdaq rules.
Three standing committees: Audit, Compensation, and Nominating & Governance, each with defined responsibilities.
The board held 10 meetings in 2023, with strong attendance.
Stockholders can communicate directly with the board and nominate directors per bylaw procedures.
Latest events from Advent Technologies
- Q4 revenue and cash fell as cost cuts and partnerships drove a shift to licensing and MEA focus.ADN
Q4 202323 Jan 2026 - Director and auditor ratified; other business matters not approved at the meeting.ADN
AGM 202410 Jan 2026 - Shareholders will vote on director elections, auditor ratification, stock issuance, and incentive plan changes.ADN
Proxy Filing1 Dec 2025 - Seeks up to $52M equity funding amid losses and going concern risk, leveraging HT-PEM tech and partnerships.ADN
Registration Filing28 Nov 2025 - Liquidity crisis persists despite improved net income; delisted, high debt, and major legal risks remain.ADN
Q3 202517 Nov 2025 - All agenda items, including director elections and plan amendments, were approved by majority vote.ADN
AGM 202522 Oct 2025 - Severe liquidity challenges, legal settlements, and a major EU grant defined the quarter.ADN
Q2 202512 Aug 2025 - Severe liquidity challenges persist despite cost cuts and a major EU grant, with going concern risks looming.ADN
Q1 202530 Jun 2025 - Revenue up 113% year-over-year, but severe liquidity risk and going concern doubts persist.ADN
Q4 202530 Jun 2025